Valor pronóstico de ERG, PTEN, SPINK1, Ki-67, RA y C-MYC en la predicción de recidiva bioquímica tras prostatectomía radical en el cáncer prostático

Abstract

Prostate cancer (PC) is highly prevalent in the developed world, and has an enormous impact on morbidity and mortality and public health costs. After RP with curative objective, 25% of patients will suffer a biochemical recurrence (BR), although only half of them will have clinical progression. Getting the correctly staging of patients according to the tumor extension and the risk of recurrence or progression would make it possible to avoid overtreatments with significant sequelae, indicating more active surveillance and avoiding unnecessary adjuvant or salvage treatments. For this task we use predictive tools like nomograms and scores constructed with different variables, such as clinicopathological, immunohistochemical biomarkers (IHC), genetic or imaging tests such as multiparametric magnetic resonance imaging (MRI).Objectives: To assess the prognostic capacity of BR of the 7 biomarkers studied by IH in a population of patients with localized PC undergoing RP. To build a predictive score of BR based on CAPRA-S together with the biomarkers that can cost-effectively improve other models or commercial multigenetic panels. Validate the score in the population and compare C-index with respect to CAPRA-S and different predictive models...